{
 "drug": "Atazanavir Sulfate; Cobicistat Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "11/03/2025",
 "dayN": 295,
 "cat": "Antiviral",
 "companies": [
  "Bristol Myers Squibb Co."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "11/03/2025",
   "update_type": "New",
   "initial_posting_date": "11/03/2025",
   "package_ndc": "0003-3641-11",
   "generic_name": "Atazanavir Sulfate; Cobicistat Tablet",
   "contact_info": "800-332-2056",
   "related_info": "The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.",
   "openfda": {
    "application_number": [
     "NDA206353"
    ],
    "brand_name": [
     "EVOTAZ"
    ],
    "generic_name": [
     "ATAZANAVIR AND COBICISTAT"
    ],
    "manufacturer_name": [
     "E.R. Squibb & Sons, L.L.C."
    ],
    "product_ndc": [
     "0003-3641"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "ATAZANAVIR SULFATE",
     "COBICISTAT"
    ],
    "rxcui": [
     "1601654",
     "1601660"
    ],
    "spl_id": [
     "fa642c67-5a9e-4136-a141-64e1236f6a0f"
    ],
    "spl_set_id": [
     "83db29d7-5d85-49d6-8cb6-740473365cf8"
    ],
    "package_ndc": [
     "0003-3641-11"
    ],
    "nui": [
     "N0000190114",
     "N0000191001",
     "N0000185503",
     "N0000182137",
     "N0000190107",
     "N0000190108",
     "N0000190113",
     "N0000191423"
    ],
    "pharm_class_moa": [
     "Cytochrome P450 3A Inhibitors [MoA]",
     "P-Glycoprotein Inhibitors [MoA]",
     "Cytochrome P450 2D6 Inhibitors [MoA]",
     "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]",
     "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]",
     "Breast Cancer Resistance Protein Inhibitors [MoA]",
     "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]"
    ],
    "pharm_class_epc": [
     "Cytochrome P450 3A Inhibitor [EPC]"
    ],
    "unii": [
     "4MT4VIE29P",
     "LW2E03M5PG"
    ]
   },
   "update_date": "11/03/2025",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)",
   "company_name": "Bristol Myers Squibb Co.",
   "status": "To Be Discontinued"
  }
 ]
}